Bausch Health Cos PE Ratio 2010-2024 | BHC

Current and historical p/e ratio for Bausch Health Cos (BHC) from 2010 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Bausch Health Cos PE ratio as of December 26, 2024 is 2.01.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Bausch Health Cos PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2024-12-26 7.61 0.00
2024-09-30 8.16 $-1.34 0.00
2024-06-30 6.97 $-1.04 0.00
2023-12-31 8.02 $-1.62 0.00
2023-09-30 8.22 $-2.64 0.00
2023-06-30 8.00 $-1.78 0.00
2023-03-31 8.10 $-0.75 0.00
2022-12-31 6.28 $-0.60 0.00
2024-03-31 10.61 $0.34 31.21
2022-09-30 6.89 $0.70 9.84
2022-06-30 8.36 $0.12 69.67
2022-03-31 22.85 $-1.14 0.00
2021-12-31 27.61 $-2.66 0.00
2021-09-30 27.85 $-3.28 0.00
2021-06-30 29.32 $-3.60 0.00
2021-03-31 31.74 $-2.86 0.00
2020-12-31 20.80 $-1.58 0.00
2020-09-30 15.54 $-5.45 0.00
2020-06-30 18.29 $-5.79 0.00
2020-03-31 15.50 $-5.36 0.00
2019-12-31 29.92 $-5.08 0.00
2019-09-30 21.85 $-1.76 0.00
2019-06-30 25.22 $-2.62 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.723B $8.757B
Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic areas of eye-health, gastroenterology (GI), and dermatology.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $25.400B 8.33
Dr Reddy's Laboratories (RDY) India $13.080B 25.03
BridgeBio Pharma (BBIO) United States $5.392B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.966B 26.77
Amphastar Pharmaceuticals (AMPH) United States $1.840B 11.06
Personalis (PSNL) United States $0.430B 0.00
Taysha Gene Therapies (TSHA) United States $0.379B 26.43
Assembly Biosciences (ASMB) United States $0.094B 0.00
Sol-Gel Technologies (SLGL) Israel $0.027B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00